Clinical

Articles

The CheckMate-816 trial is the first positive phase 3 trial demonstrating a significant improvement in pathologic response with neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer.

Neoadjuvant Nivolumab Plus Chemo Improves Pathological Complete Response in Resectable NSCLC

Videos

CancerNetwork® spoke with Nikki Martin of the LUNGevity Foundation regarding the “No One Missed” campaign working to provide education and awareness to patients with lung cancer.

Nikki Martin on LUNGevity’s “No One Missed Campaign” Focusing on Biomarker Testing Access

The Virtual Nodule Clinic artificial intelligence–powered clinical decision support tool was cleared by the FDA for detection of early-stage lung cancer in lung nodules detected by a CT scan. 

Diagnostic AI Tool for Identifying Early-Stage Lung Cancer Earns FDA 150(k) Clearance 

Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.


Study Results Appear to Support Larotrectinib Use in NTRK+ Lung Cancer  

Study Shows Increase in Lung Cancer Mortality, Decrease in Diagnosis During COVID-19 Pandemic

“With recent advances in early detection of lung cancer, biomarker testing, and personalized treatment planning, effective patient-provider communication is more important than ever for short- and long-term survivorship,” said Kelly Clark, MA.


Further Patient Education by Clinicians Is Necessary to Facilitate Better Decision Making

The combination of tiragolumab and atezolizumab (Tecentriq) was granted breakthrough therapy designation based on promising efficacy and safety data observed in the phase 2 CITYSCAPE trial.

FDA Grants Breakthrough Therapy Designation to Tiragolumab Combo for PD-L1-High NSCLC

Under the FDA’s Real-Time Oncology Review Pilot Program and Project ORBIS, the FDA is reviewing a supplemental new drug application for lorlatinib (Lorbrena) as a first-line treatment for patients with ALK-positive metastatic non–small cell lung cancer.

FDA Grants Priority Review to sNDA for Lorlatinib in Previously Untreated ALK+ NSCLC

The Emory University Winship Cancer Institute expert discussed FDA approvals and other treatment advances that occurred this year.

Jennifer W. Carlisle, MD, Offers Perspective on Lung Cancer Advances in 2020

This study found that among patients with lung cancer from Latin America, Native American ancestry was associated with increased mutations in the EGFR gene, independent of smoking status. 

Lung Cancer | Topics